House Dust Mite Allergy and Immunotherapy

House dust mite allergy represents one of the most prevalent forms of indoor respiratory hypersensitivity worldwide. Dermatophagoides pteronyssinus and Dermatophagoides farinae release proteinaceous allergens—most notably Der p 1 and Der f 1—that provoke an IgE-mediated Type I immune response in susceptible individuals. Allergen exposure triggers mast cell degranulation and a cascade of Th2-driven inflammation, resulting in symptoms ranging from allergic rhinitis to asthma. Component-resolved diagnosis has refined the identification of sensitisation profiles, enabling more precise patient stratification. Allergen immunotherapy remains the only disease-modifying treatment, seeking to induce long-term tolerance through controlled administration of mite extracts or recombinant components. Conventional subcutaneous and sublingual regimens have demonstrated efficacy in reducing symptom severity and medication use, yet concerns over safety, duration and individual variability in response persist. Recent advances focus on optimised dosing schedules, novel adjuvants, peptide-based vaccines and biologics targeting key cytokines to enhance efficacy and reduce adverse reactions. Ongoing efforts aim to integrate molecular diagnostics with personalised immunotherapy protocols, thereby improving outcomes and addressing the global burden of mite allergy.

Research from Nature Portfolio

No recent Nature Portfolio content available.

House Dust Mite Allergy and Immunotherapy publication trend

The graph below shows the total number of articles in house dust mite allergy and immunotherapy across all publications each year (not limited to Nature Index journals).

Technical terms

Allergen immunotherapy: Treatment involving repeated administration of allergen extracts to induce immune tolerance.

Immunoglobulin E (IgE): Antibody class responsible for mediating immediate hypersensitivity reactions.

Sublingual immunotherapy (SLIT): Delivery of allergen formulations under the tongue to achieve desensitisation.

Sensitisation: Process by which initial allergen exposure primes the immune system to overreact on subsequent encounters.

Epitopes: Specific molecular regions of an allergen recognised by antibodies or T cell receptors.

References

1. Serological analysis of allergic components of house dust mite provides more insight in epidemiological characteristics and clinical symptom development in North China. Frontiers in Immunology (2023).
2. A hypoallergenic peptide mix containing T cell epitopes of the clinically relevant house dust mite allergens. Allergy (2019).
3. International consensus (ICON) on: clinical consequences of mite hypersensitivity, a global problem. World Allergy Organization Journal (2017).